Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)

About this funding opportunity

This Notice of Funding Opportunity (NOFO) encourages collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science. This NOFO will support clinical trials that test functionality or validate performance in the chosen setting. This NOFO is not intended to support conventional clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of research are not sought by and will not be supported through this NOFO. This NOFO does not support commercial production.

Topic areas: Life Sciences and Health, Advanced Manufacturing and Industry, General and Cross-cutting R&D.

Funding amount

This grant provides Up to $500K in funding, up to $500K per award.

Deadline

Applications are due Jul 05, 2029. Confirm the exact closing time on the official program page before applying.

Who can apply

This opportunity is open to the following applicant types:

• Public Authorities
• Large Company
• Other
• NGOs
• University
• SME

Eligibility

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Agency

Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) is administered by National Institutes of Health (NIH), listed via Grants.gov.